WG
ALXN

Winton Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Winton Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,322
Closed -$978K – 1531
2021
Q2 		$978K Buy
5,322
+903
+20% +$155K 0.05% 541
2021
Q1 		$676K Buy
+4,419
New +$684K 0.04% 708
2020
Q4 		– Sell
-13,679
Closed -$1.56M – 1598
2020
Q3 		$1.56M Buy
13,679
+4,766
+53% +$514K 0.05% 643
2020
Q2 		$1M Buy
+8,913
New +$946K 0.03% 963
2017
Q4 		– Sell
-56,599
Closed -$7.94M – 725
2017
Q3 		$7.94M Buy
56,599
+54,164
+2,224% +$7.36M 0.25% 105
2017
Q2 		$296K Buy
+2,435
New +$283K 0.01% 568
2014
Q3 		– Sell
-16,703
Closed -$2.61M – 689
2014
Q2 		$2.61M Buy
+16,703
New +$2.64M 0.02% 426

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Winton Group's ALXN Position: Q3 2021 in Review

Winton Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 5,322 shares — an estimated $978K sold.

Winton Group first reported a position in ALXN in Q2 2014 and held it in 7 quarters. The position peaked at $7.94M in Q3 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Winton Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Winton Group sold 5,322 Alexion Pharmaceuticals shares in Q3 2021, an estimated $978K.
  • Winton Group first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 7 quarters.
  • Winton Group's Alexion Pharmaceuticals position peaked at $7.94M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Winton Group's 13F filing for Q3 2021, filed 28 Oct 2021.